XTL Biopharmaceuticals Establishes U.S. Operations / Glenn Kazo Appointed Vice President, Business Development and General Manager -

Rehovot, Israel and New Ipswich, N.H. (PROTEXT) - XTLBiopharmaceuticals, Ltd. announced today the establishment of asubsidiary, XTL Biopharmaceuticals, Inc., with operations basedin New Hampshire (United States). Glenn M. Kazo has beenappointed Vice President of Business Development and GeneralManager of Company operations in the United States. "XTL's establishment of a firm foothold in the U.S. willfacilitate direct access to the world's largest market forpharmaceutical- and biotechnology- based products," stated MartinBecker, Ph.D., President and Chief Executive Officer of XTL. "Ouroperations in the U.S. will support XTL's business developmentactivities and will lay the foundation for efficient introductionof XTL's product candidates into the American regulatoryenvironment. Furthermore, we are pleased to welcome Glenn, andhis broad range of expertise in the biopharmaceutical industry,to our team." Prior to joining XTL, Mr. Kazo served as Vice President,Corporate Development at Focal, Inc., a public medical devicefirm in Lexington, MA. Additionally, he was a founding member ofEnzon, Inc., a leading drug delivery company, where he pioneeredthe development of two of the company's marketed drug products.Mr. Kazo's expertise ranges from technical pharmaceutical productdevelopment to business development, licensing, mergers andacquisitions, finance, sales and marketing, communications andoperations. Mr. Kazo has over 15 years of experience in businessdevelopment, strategic planning and general management for thebiopharmaceutical industry, and he has managed a consultingpractice focusing on emerging technologies. XTL has recently initiated a Phase I study of XTL001, aninvestigational monoclonal antibody (MAb) product, to evaluatethe safety profile and antiviral activity of the compound inpatients chronically infected with hepatitis B virus (HBV). TheCompany has also signed an agreement to test an Eli Lilly &Company drug candidate in XTL's proprietary animal model forhepatitis C (HCV). The Trimera(XTL) system is a breakthrough,patented method, which enables a mouse to carry human liverfragments infected with HCV, thus offering the potential tobiologically validate the effectiveness of drug candidates beforeembarking on costly human clinical studies. For further information on XTL Biopharmaceuticals, Inc.,please contact Glenn Kazo at (603) 878 9857. XTL is a biopharmaceutical company developing fully humanmonoclonal antibody-based therapeutics with a primary focus oninfectious diseases. The Company applies its proprietary drugdiscovery and development "engine," the Trimera(XTL) system, toproduce high affinity, fully human antibodies to a broad range ofdisease targets including hepatitis B (HBV) and hepatitis C(HCV). In addition, XTL has unique, high-value animal models ofhuman diseases including models for testing HBV and HCVtherapeutic drugs. For more information about XTL, visit theCompany's website at http://www.xtlbio.com. ots Original TextService: XTL Biopharmaceuticals, Ltd. Internet:http://www.newsaktuell.de Contact: Glenn Kazo, Vice President,Business Development and General Manager of XTLBiopharmaceuticals, Inc., (USA) 603-878-9857, orgkazo@xtlbio.com, or in Israel: Martin Becker, Ph.D., Presidentand CEO of XTL Biopharmaceuticals, Ltd., +972-8-940-5134, orbecker@xtlbio.com; or Douglas MacDougall or Kari Lampka, bothof Feinstein Kean Partners Inc. (USA) 617-577-8110, for XTLBiopharmaceuticals Web site: http://www.xtlbio.com

Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.

PROTEXT